PRESS / PUBLICATIONS
CARE in the press
23/04/2022
COVID CARE: antibody mapping detects vulnerable spike sites, and another promising antiviral emerges
IMI Press release
12/10/2021
Scientists discover highly potent antibody effective against SARS-CoV-2 variants
CHUV Press release
10/05/2021
Closing in on COVID: results from the first year of CARE
IMI News
22/04/2021
The race for antiviral drugs to beat COVID — and the next pandemic
Nature
06/10/2020
Covid-19: on the way for future treatments (in French)
Le Monde
29/09/2020
Project of the Month: Europe’s largest initiative officially launched to accelerate treatments for COVID-19
European Commission – Cordis News
31/08/2020
CARE is preparing for the new normal
IMI Press release
CARE embarks on an unprecedented mission to get ready for coming COVID-19 waves and new coronavirus outbreaks.
17/08/2020
EFPIA CARE presentation
CARE: A new consortium against COVID-19 supported by the Innovative Medicines Initiative (IMI)
CARE External Newsletter
27/06/2024
CARE 4th External Newsletter
Newsletter explaining cryo-EM and how this exciting new technology is benefiting our scientific endeavours across CARE, plus introducing 3 CARE partners: Utrecht University and the Institute for Virology and Immunology (academic organisations) and Nuvisan (industry organisation)
20/12/2023
CARE 3rd External Newsletter
Newsletter sharing EC sponsored workshop recommendations about pandemic preparedness and ask how these have been taken forward into action. We also take a closer look at two of our partners: Iktos and Leiden University Medical Center.
30/06/2023
CARE 2nd External Newsletter
Newsletter explaining why CARE still cares even if the publich health emergency is over, presenting results from COVID-19 cohorts, introducing CARE partner Ai-biopharma (a SME) and summarizing CARE 3rd Annual meeting.
15/12/2022
CARE 1st External Newsletter
Newsletter presenting the CARE consortium, some of CARE publications and an example of CARE collaboration in Action. We also announce the launch of CARE LinkedIn account.
CARE publications
Neutralizing antibodies reveal cryptic vulnerabilities and interdomain crosstalk in the porcine deltacoronavirus spike protein
Wenjuan Du, Oliver Debski-Antoniak, Dubravska Drabek et al.
Nature Communications, 2024, 15, 5330
Modulation of nucleotide metabolism by picornaviruses
Lonneke Nouwen, Martijn Breeuwsma, Esther Zaal et al.
Plos Pathogens, 2024, 20(3):e1012036
Assessment of Kinome-wide Activity Remodeling Upon Picornavirus Infection
Tim Veth, Lonneke Nouwen, Marleen Zwaagstra et al.
Molecular & cellumar proteomics, 2024, 23(5):100757
SARS-CoV-2 Mpro oligomerization as a potential target for therapy
Kinga Lis, Jacek Plewka, Filipe Menezes et al.
International Journal of Biological Macromolecules, 2024, 267:131392
Despite the odds: formation of the SARS-CoV-2 methylation complex
Alex Matsuda, Jacek Plewska, Andre Mourao et al.
Nucleic Acids Research, 2024, 1-18
Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters
Rana Abdelnabi, Ria Lassaunière, Piet Maes et al.
Viruses, 2024, 16(1):122
A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects
Jordi Doijen, Inha Heo, Koen Temmerman et al.
Antiviral Res., 2024, 222:105789
An engineered A549 cell line expressing CD13 and TMPRSS2 is permissive to clinical isolate of human coronavirus 229E
Laurensius Kevin Lie, Aleksandra Synowiec, Jedrzei Mazur et al.
Virology, 2023, 588:109889
Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery
Winston Chiu, Joost Schepers, Thibault Francken et al.
Antiviral Res., 2023, 210:105506
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys
Craig Fenwick, Priscilla Turelli, Yoan Duhoo et al.
Journal of Infection, 2023, 87(6):524-537
A broad-spectrum macrycyclic peptide inhibitor of the SARS-CoV-2 spike protein
Vito Thijssen, Daniel Hurdliss, Oliver Debski-Antoniak et al.
Proc NAtl Sci USA, 2023, 120(6):e2303292120
Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases
Marcel Hausdorff, Adrien Delpal, Sarah Barelier et al.
Eur J Med Chem, 2023, 256:115474
The application of data altruism in clinical research through empirical and legal analysis lenses
Teodora Lalova-Spinks, Janos Meszaros & Isabelle Huys
Front Med, 2023, 10:11416852
Neutrophil activation and immune thrombosis profiles persist in convalescent COVID-19
Hakim Hocini, Aurélie Wiedemann, Fabiola Blengio et al.
J Clin Immunol, 2023, Mar 21;1-12
Identification of of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
Denisa Bojkova, Philipp Reus, Leona Panosch et al.
iScience, 2023, 26(2) 105944
Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2
Jordi Doijen, Koen Temmerman, Christel Van der Eynde et al.
Microorganisms, 2023, 11(3) 717
CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses
Alessandra Noto, Victor Joo, Antonio Mancarella et al.
Viruses, 2022,14(12):2665
Potent Inhibition of SARS-CoV-2 nsp14 N 7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues
Rostom Ahmed-Belkacem, Marcel Hausdorff, Adrien Delpal et al.
J Med Chem, 2022, 65(8):6231-6249
Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study.
Yuao Zhu, Joe Binder, Irina Yurgelonis et al.
Antiviral Res, 2022, 208:155429
Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
Rana Abdelnabi, Piet Maes, Steven de Jonghe et al.
Frontiers in Pharmacology, 2022, 13:1072202
A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection.
Rana Abdelnabi, Caroline Foo, Suzanne Kaptein et al.
Journal of Virology, 2022, 96(16): e00758-22
Challenges related to data protection in clinical research before and during the COVID-19 pandemic: an exploratory study
Teodora Lalova-Spinks, Evelien De Sutter, Peggy Valcke et al.
Frontiers in Medicine, 2022, 9: 995689
Rethinking informed consent in the time of COVID-19: an exploratory survey
Evelien De Sutter, Teodora Lalova-Spinks, Pascal Borry et al.
Frontiers in Medicine, 2022, 9: 995688
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 omicron variants and confers full protection in monkeys
Craig Fenwick, Priscilla Turelli, Dongchun Ni et al.
Nature Microbiology, 2022, 7: 1376-1389
Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity
Anna Czarna, Jacek Plewska, Leanid Kresik et al.
Structure, 2022, 30(8): 1050-1054
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
Séverin Coléon, Aurélie Wiedemann, Mathieu Surénaud et al.
EBioMedicine, 2022, 80: 104062
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Michel Obeid, Madeleine Suffiotti, Celine Pellaton et al.
JAMA Oncol., 2022, 8(5) e220446
Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication
Dorothée Bardiot, Laura Vangeel, Mohamed Koukni et al.
Molecules, 2022, 27(3) 1052
Computed Tomography and [18 F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates
Thibaut Naninck, Nidhal Kahlaoui, Julien Lemaitre et al.
IScience, 2022, 4:144101
Development and optimization of a high-throughput screening assay for un vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures
Winston Chiu, Lore Verschuerent, Christel Van den Eynde et al.
J Med Virol, 2022, 94(7) 31013111
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern
Laura Vangeel, Winston Chiu, Steven De Jonghe et al.
Antiviral Res, 2022, 198:105252
A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase
Ashleigh Shannon, Véronique Fattorini, Bhawna Sama et al.
Nat Commun, 2022, 13:621
High Throughput cryo-EM epitope mapping of SARS-CoV-2 spike protein antibodies using EPU multigrid
Ieva Drulyte, Stefan Koester, Dianna Lundberg et al.
White paper with ThermoFischer Scientific, 20212
A highly potent antibody effective against SARS-CoV-2 variants of concern
Craig Fenwick, Priscilla Turelli, Laurent Perez et al.
Cell reports, 2021, 37(2):109814
Shape-Restrained Modeling of Protein-Small-Molecule Complexes with High Ambiguity Driven DOCKing
Panagiotis Koukos, Manon Réau and Alexandre Bonvin
J. Chem. Inf. Model., 2021, 61(9):4807-4818
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma
Craig Fenwick, Priscilla Turelli, Céline Pellaton et al.
Science Translational Medicine, 2021, 13(605):eabi8452
CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death
Yves Lévy, Aurélie Wiedemann, Boris P. Hejblum et al.
iScience, 2021, 24:102711
Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells
Ian R. McCracken, Gaye Saginc, Liqun He et al.
Circulation, 2021, 143:865-868
Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies
Craig Fenwick, Antony Croxatto, Alix Coste et al.
Journal of Virology, 2021, 95(3): e01828-20
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse, Jérémie Guedj, Vanessa Contreras et al.
Nature, 2020, 585: 584-587